| abstract |
A medicinal composition for treating tardive dyskinesia, which contains a compound having a phosphodiesterase inhibitory activity as the active ingredient, a preferable example thereof being rolipram. When this compound is administered to an experimental model of tardive dyskinesia induced by the chronic administration of haloperidol to rats, it exhibits a therapeutic effect of suppressing the symptom of tardive dyskinesia in a dose-dependent manner. |